Companion Animal Vaccines Market Volume Analysis, Segments, Value Share and Key Trends 2016-2026
Companion animal vaccines are used to stimulate an immune response in pets such as canine, avian and feline. These vaccine products are of various types such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live vaccines are derived from disease-causing pathogens such as virus or bacteria, which have been weakend under laboratory conditions. Conjugate vaccines are an antigen or toxoid-containing preparation that is linked to polysaccharides and stimulate the immature immune system to defend against the disease-causing organism. Inactivated vaccines are made from microorganisms such as viruses and bacteria that have been killed through physical or chemical processes. Subunit vaccines, like inactivated whole-cell vaccines, do not contain live components of the pathogen. Toxoid vaccines are based on the toxin produced by certain bacteria, which is rendered harmless and used as the antigen in the vaccine to elicit an immune response. DNA vaccines are manufactured by inserting DNA into a bacterial plasmid, which functions as the vector. Recombinant vaccines are produced by genetic engineering technology and use attenuated virus or bacterium as a vector to introduce microbial DNA to the cells of the body. The global companion animal vaccines market was valued at more than US$ 2,100 Mn in 2015 and is projected to register a CAGR of 6.8% during the forecast period. The market is expected to be valued at nearly US$ 4,500 Mn by the end of 2026. Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1427
Companion animal vaccines are used to stimulate an immune response in pets such as canine, avian and feline. These vaccine products are of various types such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated live vaccines are derived from disease-causing pathogens such as virus or bacteria, which have been weakend under laboratory conditions. Conjugate vaccines are an antigen or toxoid-containing preparation that is linked to polysaccharides and stimulate the immature immune system to defend against the disease-causing organism. Inactivated vaccines are made from microorganisms such as viruses and bacteria that have been killed through physical or chemical processes. Subunit vaccines, like inactivated whole-cell vaccines, do not contain live components of the pathogen. Toxoid vaccines are based on the toxin produced by certain bacteria, which is rendered harmless and used as the antigen in the vaccine to elicit an immune response. DNA vaccines are manufactured by inserting DNA into a bacterial plasmid, which functions as the vector. Recombinant vaccines are produced by genetic engineering technology and use attenuated virus or bacterium as a vector to introduce microbial DNA to the cells of the body.
The global companion animal vaccines market was valued at more than US$ 2,100 Mn in 2015 and is projected to register a CAGR of 6.8% during the forecast period. The market is expected to be valued at nearly US$ 4,500 Mn by the end of 2026.
Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1427
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Companion</strong> <strong>Animal</strong> <strong>Vaccines</strong> <strong>Market</strong><br />
According to Future <strong>Market</strong> Insights’ research, lack of information on emerging virulent veterinary<br />
diseases, <strong>and</strong> decline sales revenues through veterinarians can stifle dem<strong>and</strong> for companion animal<br />
vaccines during the forecast period. The longst<strong>and</strong>ing challenges with correctly identifying <strong>and</strong><br />
underst<strong>and</strong>ing antigen/immunogenic structures can also negatively impact the growth of the market.<br />
Nearly US$ 764 Mn worth of attenuated live vaccines were sold globally in <strong>2016</strong>. This segment is<br />
projected to grow at a CAGR of 7.3% during the forecast period <strong>2016</strong>-<strong>2026</strong>.<br />
Distribution Channel <strong>Analysis</strong>: Veterinary Clinics will Remain the Preferred Distribution Channel<br />
Veterinary clinics continue to be the preferred distribution channel for pharma companies, followed by<br />
veterinary hospitals. These two point of care centres witness substantial footfall of pet owners all year<br />
round, <strong>and</strong> drug companies continuously focus on increasing sales through these channels. In <strong>2016</strong>, these<br />
two distribution channels collectively accounted for nearly 75% revenue share of the market. By the end<br />
of forecast period, the status quo is expected to remain unchanged. Retail pharmacies, which held 20%<br />
share of the market in <strong>2016</strong>, will grow at the highest CAGR during the forecast period.<br />
North America - Largest <strong>Market</strong> for <strong>Companion</strong> <strong>Animal</strong> <strong>Vaccines</strong><br />
The U.S. continues to be a leading market for companion animal vaccines. High level of awareness among<br />
pet owners, combined with easy availability of pet healthcare have resulted into the growth of the<br />
market in the U.S. On account of strong dem<strong>and</strong> in the U.S., North America will continue to be the largest<br />
market globally.<br />
©2015 Future <strong>Market</strong> Insights, All Rights Reserved 5
Change language